|
| Authors, year | Study type | Treatment | Outcome |
|
| Mirmirani and Karnik, 2009 [52] | Case report:
(i) 1 patient with LPP | (i) Oral pioglitazone hydrochloride 15 mg/day for 14 months | (i) 2 months: clinical improvement
(ii) 6 months: marked decrease of inflammation
(iii) 1 year: remained symptom-free |
|
| Baibergenova and Walsh, 2012 [53] | Case series:
(i) 21 patients with LPP
(ii) 2 patients with FAPD
(iii) 1 patient with FFA | (i) Oral pioglitazone hydrochloride 15 mg/day, increased to 30 mg/day if there is no ADR
(ii) Concurrent treatments were variably used as needed | (i) 5 patients: remission
(ii) 12 patients: improvement
(iii) 3 patients: no improvement
(iv) ADR in 4 patients leading to withdrawal: calf pain, lightheadedness, dizziness and hives |
|
| Spring et al., 2013 [54] | Case series:
(i) 22 patients with LPP | (i) Oral pioglitazone hydrochloride 15 mg/day for 1 year
(ii) Adjuvant treatments were variably used as needed | (i) 3 patients: remission and no relapse
(ii) 5 patients: improvement with lower disease activity
(iii) 4 patients: improvement but symptoms relapsed
(iv) 10 patients: negative result |
|
| Mesinkovska et al., 2015 [55] | Case series:
(i) 18 patients with LPP
(ii) 4 patients with FFA | (i) Oral pioglitazone hydrochloride 15 mg/day for median of 10.5 months | (i) 16 patients: marked improvement
(ii) 5 patients: stable of disease
(iii) 1 patient: progression of disease
(iv) ADR: lower extremities edema, weight gain, dizziness, resistant hypertension, mild transaminitis |
|
